Published in Arthritis Res Ther on June 24, 2014
"You want to get on with the rest of your life": a qualitative study of health-related quality of life in gout. Clin Rheumatol (2015) 0.83
Spatiotemporal gait parameters and plantar pressure distribution during barefoot walking in people with gout and asymptomatic hyperuricemia: comparison with healthy individuals with normal serum urate concentrations. J Foot Ankle Res (2016) 0.77
A joint effort over a period of time: factors affecting use of urate-lowering therapy for long-term treatment of gout. BMC Musculoskelet Disord (2016) 0.75
Racial differences in health-related quality of life and functional ability in patients with gout. Rheumatology (Oxford) (2016) 0.75
Discordant American College of Physicians and international rheumatology guidelines for gout management: consensus statement of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN). Nat Rev Rheumatol (2017) 0.75
Gout and comorbidity: a nominal group study of people with gout. Arthritis Res Ther (2017) 0.75
Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum (2008) 13.08
EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis (2006) 6.36
Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum (2011) 6.36
2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) (2012) 5.22
Loss of self: a fundamental form of suffering in the chronically ill. Sociol Health Illn (1983) 4.73
The nominal group technique: a research tool for general practice? Fam Pract (1993) 3.42
Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc (2006) 2.96
Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study. Ann Rheum Dis (2012) 2.20
Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans. Ann Rheum Dis (2008) 2.19
Quality of care for gout in the US needs improvement. Arthritis Rheum (2007) 1.93
Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD). Rheumatology (Oxford) (2005) 1.85
The prevalence and prophylaxis of gout in England. J Clin Epidemiol (1995) 1.75
Serum urate levels and gout flares: analysis from managed care data. J Clin Rheumatol (2006) 1.70
Nominal group technique: a process for identifying diabetes self-care issues among patients and caregivers. Diabetes Educ (2000) 1.65
Patients and providers view gout differently: a qualitative study. Chronic Illn (2010) 1.60
Is gout associated with reduced quality of life? A case-control study. Rheumatology (Oxford) (2007) 1.55
Gout in ambulatory care settings in the United States. J Rheumatol (2008) 1.52
Patient and provider barriers to effective management of gout in general practice: a qualitative study. Ann Rheum Dis (2012) 1.50
Sex differences in gout epidemiology: evaluation and treatment. Ann Rheum Dis (2006) 1.39
Uric acid lowering therapy: prescribing patterns in a large cohort of older adults. Ann Rheum Dis (2007) 1.39
Adherence with urate-lowering therapies for the treatment of gout. Arthritis Res Ther (2009) 1.35
Opportunities for improving medication use and monitoring in gout. Ann Rheum Dis (2008) 1.32
Perceptions of disease and health-related quality of life among patients with gout. Rheumatology (Oxford) (2009) 1.27
A revised estimate of the burden of illness of gout. Curr Ther Res Clin Exp (2013) 1.23
Patients' knowledge and beliefs concerning gout and its treatment: a population based study. BMC Musculoskelet Disord (2012) 1.15
Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: Results from a cross-sectional survey. Health Qual Life Outcomes (2012) 1.13
Gout-related health care utilization in US emergency departments, 2006 through 2008. Arthritis Care Res (Hoboken) (2013) 1.10
Use of the Nominal Group Technique (NGT) to understand the perceptions of the healthiness of foods associated with African Americans. Eval Program Plann (2009) 1.06
Illness perceptions in patients with gout and the relationship with progression of musculoskeletal disability. Arthritis Care Res (Hoboken) (2011) 1.06
Sleep problems in patients with rheumatoid arthritis. J Rheumatol (2013) 1.05
Consulting about priorities for the NHMRC National Breast Cancer Centre: how good is the nominal group technique. Aust N Z J Public Health (1997) 1.03
Nominal group technique: a brainstorming tool for identifying areas to improve pain management in hospitalized patients. J Hosp Med (2011) 1.01
Sleep disturbances and interleukin 6 receptor inhibition in rheumatoid arthritis. J Rheumatol (2011) 1.00
Racial and gender disparities among patients with gout. Curr Rheumatol Rep (2013) 0.98
The experience and impact of living with gout: a study of men with chronic gout using a qualitative grounded theory approach. J Clin Rheumatol (2011) 0.98
A Patient-Based Needs Assessment for Living Well with Parkinson Disease: Implementation via Nominal Group Technique. Parkinsons Dis (2013) 0.93
Arthritis care: comparison of physicians' and patients' views. Semin Arthritis Rheum (2000) 0.93
Challenges faced by patients in gout treatment: a qualitative study. J Clin Rheumatol (2014) 0.91
Long-term therapy for chronic gout results in clinically important improvements in the health-related quality of life: short form-36 is responsive to change in chronic gout. Rheumatology (Oxford) (2010) 0.89
Effect of acute gouty arthritis on sleep patterns: a preclinical study. Eur J Pain (2008) 0.88
Outcome indicators in palliative care--how to assess quality and success. Focus group and nominal group technique in Germany. Support Care Cancer (2009) 0.88
Research priorities in gout: the patient perspective. J Rheumatol (2014) 0.85
African American patients with gout: efficacy and safety of febuxostat vs allopurinol. BMC Musculoskelet Disord (2012) 0.81
Identifying problems in community health promotion: an illustration of the Nominal Group Technique in AIDS education. J R Soc Health (1996) 0.80
Sleep disturbances in patients with rheumatoid arthritis. Niger J Med (2013) 0.78
[Importance of the obstructive sleep apnea disorder for perioperative medicine]. Rev Med Inst Mex Seguro Soc (2007) 0.77
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 41.47
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 26.95
The state of US health, 1990-2010: burden of diseases, injuries, and risk factors. JAMA (2013) 10.43
2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) (2012) 5.22
Total knee arthroplasty volume, utilization, and outcomes among Medicare beneficiaries, 1991-2010. JAMA (2012) 4.89
Health Effects of Overweight and Obesity in 195 Countries over 25 Years. N Engl J Med (2017) 3.90
Development of classification and response criteria for rheumatic diseases. Arthritis Rheum (2006) 2.88
2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken) (2012) 2.83
Classification criteria in rheumatic diseases: a review of methodologic properties. Arthritis Rheum (2007) 2.41
Anakinra for rheumatoid arthritis: a systematic review. J Rheumatol (2009) 1.82
Abatacept for rheumatoid arthritis. Cochrane Database Syst Rev (2009) 1.68
Opioid use by patients in an orthopedics spine clinic. Arthritis Rheum (2005) 1.64
Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2015: the Global Burden of Disease Study 2015. Lancet HIV (2016) 1.51
Improved health-related quality of life and physical function in patients with refractory chronic gout following treatment with pegloticase: evidence from phase III randomized controlled trials. J Rheumatol (2012) 1.48
Clinically important body weight gain following knee arthroplasty: a five-year comparative cohort study. Arthritis Care Res (Hoboken) (2013) 1.46
Anakinra for rheumatoid arthritis. Cochrane Database Syst Rev (2009) 1.41
Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials. Am J Manag Care (2007) 1.35
Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity. Drugs (2010) 1.32
Use of biologics in rheumatoid arthritis: current and emerging paradigms of care. Clin Ther (2011) 1.29
Perceptions of disease and health-related quality of life among patients with gout. Rheumatology (Oxford) (2009) 1.27
Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor. Clin Ther (2012) 1.23
Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials. Am J Manag Care (2008) 1.21
Update of strategies to translate evidence from cochrane musculoskeletal group systematic reviews for use by various audiences. J Rheumatol (2013) 1.18
Abatacept for rheumatoid arthritis: a Cochrane systematic review. J Rheumatol (2010) 1.18
OARSI/OMERACT initiative to define states of severity and indication for joint replacement in hip and knee osteoarthritis. An OMERACT 10 Special Interest Group. J Rheumatol (2011) 1.14
How to choose core outcome measurement sets for clinical trials: OMERACT 11 approves filter 2.0. J Rheumatol (2014) 1.11
Developing a provisional definition of flare in patients with established gout. Arthritis Rheum (2012) 1.10
Progress in measurement instruments for acute and chronic gout studies. J Rheumatol (2009) 1.06
Validation of administrative codes for calcium pyrophosphate deposition: a Veterans Administration study. J Clin Rheumatol (2015) 1.03
The establishment of the GENEQOL consortium to investigate the genetic disposition of patient-reported quality-of-life outcomes. Twin Res Hum Genet (2009) 1.03
Comparison of patient-reported and clinician-assessed outcomes following total knee arthroplasty. J Bone Joint Surg Am (2011) 1.02
Variation in outcome measures in hip and knee arthroplasty clinical trials: a proposed approach to achieving consensus. J Rheumatol (2009) 1.01
Harms of TNF inhibitors in rheumatic diseases: a focused review of the literature. Immunotherapy (2013) 0.99
Adverse effects of smoking on postoperative outcomes in cancer patients. Ann Surg Oncol (2011) 0.99
TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev (2015) 0.98
Facilitators and barriers to adherence to urate-lowering therapy in African-Americans with gout: a qualitative study. Arthritis Res Ther (2014) 0.97
Leflunomide use during the first 33 months after food and drug administration approval: experience with a national cohort of 3,325 patients. Arthritis Rheum (2003) 0.95
Efficacy of intra-articular botulinum toxin type A in painful knee osteoarthritis: a pilot study. PM R (2010) 0.94
Total knee arthroplasty in morbidly obese patients treated with bariatric surgery: a comparative study. J Arthroplasty (2012) 0.94
Diagnosis and management of infected total knee arthroplasty. Open Orthop J (2011) 0.92
Serum urate in chronic gout--will it be the first validated soluble biomarker in rheumatology? J Rheumatol (2011) 0.92
Intra-articular Botulinum Toxin Type A: a new approach to treat arthritis joint pain. Toxicon (2009) 0.90
Improving the efficiency and effectiveness of pragmatic clinical trials in older adults in the United States. Contemp Clin Trials (2012) 0.89
Bringing it all together: a novel approach to the development of response criteria for chronic gout clinical trials. J Rheumatol (2011) 0.88
Botulinum toxin therapy for osteoarticular pain: an evidence-based review. Ther Adv Musculoskelet Dis (2010) 0.87
Predictors of use of pain medications for persistent knee pain after primary Total Knee Arthroplasty: a cohort study using an institutional joint registry. Arthritis Res Ther (2012) 0.87
Biologicals for rheumatoid arthritis. BMJ (2011) 0.87
Tophus measurement as an outcome measure for clinical trials of chronic gout: progress and research priorities. J Rheumatol (2011) 0.87
Biological pathways, candidate genes, and molecular markers associated with quality-of-life domains: an update. Qual Life Res (2014) 0.86
Minimally important differences of the gout impact scale in a randomized controlled trial. Rheumatology (Oxford) (2011) 0.86
Use of breath carbon monoxide measurements to assess erythrocyte survival in subjects with chronic diseases. Am J Hematol (2006) 0.86
Veterans Affairs databases are accurate for gout-related health care utilization: a validation study. Arthritis Res Ther (2013) 0.85
The influence of the contralateral knee prior to knee arthroplasty on post-arthroplasty function: the multicenter osteoarthritis study. J Bone Joint Surg Am (2013) 0.85
Patient understanding and satisfaction in informed consent for total knee arthroplasty: a randomized study. Arthritis Care Res (Hoboken) (2011) 0.85
Patient race and surgical outcomes after total knee arthroplasty: an analysis of a large regional database. Arthritis Care Res (Hoboken) (2013) 0.85
Participation following knee replacement: the MOST cohort study. Phys Ther (2013) 0.84
Pegloticase for chronic gout. Cochrane Database Syst Rev (2010) 0.83
Updated method guidelines for cochrane musculoskeletal group systematic reviews and metaanalyses. J Rheumatol (2013) 0.82
Predictors of doctor-rated and patient-rated gout severity: gout impact scales improve assessment. J Eval Clin Pract (2010) 0.82
Assessment of physical function and participation in chronic pain clinical trials: IMMPACT/OMERACT recommendations. Pain (2016) 0.82
Investigational drugs for hyperuricemia. Expert Opin Investig Drugs (2015) 0.81
Biomarkers in arthroplasty: a systematic review. Open Orthop J (2011) 0.80
Applying science in practice: the optimization of biological therapy in rheumatoid arthritis. Arthritis Res Ther (2010) 0.80
Including health equity considerations in development of instruments for rheumatology research: an introduction to a novel OMERACT paradigm. J Rheumatol (2013) 0.79
Updating the OMERACT filter: core areas as a basis for defining core outcome sets. J Rheumatol (2014) 0.79
Application of the OMERACT filter to measures of core outcome domains in recent clinical studies of acute gout. J Rheumatol (2014) 0.79
The relation between cancer patient treatment decision-making roles and quality of life. Cancer (2013) 0.79
Does clinically important change in function after knee replacement guarantee good absolute function? The multicenter osteoarthritis study. J Rheumatol (2013) 0.79
Outcome measures in acute gout: a systematic literature review. J Rheumatol (2013) 0.79
Gout in the Hmong in the United States. J Clin Rheumatol (2010) 0.78
OMERACT 11: international consensus conference on outcome measures in rheumatology. J Rheumatol (2014) 0.78
Updating the OMERACT filter: implications of filter 2.0 to select outcome instruments through assessment of "truth": content, face, and construct validity. J Rheumatol (2014) 0.78
Spondyloarthropathy: an independent risk factor for kidney stones. J Endourol (2006) 0.78
Updating the OMERACT filter: discrimination and feasibility. J Rheumatol (2014) 0.78
Updating the OMERACT filter: implications for imaging and soluble biomarkers. J Rheumatol (2014) 0.77
Folic acid supplementation for rheumatoid arthritis patients on methotrexate: the good gets better. Cochrane Database Syst Rev (2013) 0.77
OMERACT 10 Patient Perspective Virtual Campus: valuing health; measuring outcomes in rheumatoid arthritis fatigue, RA sleep, arthroplasty, and systemic sclerosis; and clinical significance of changes in health. J Rheumatol (2011) 0.77
Using tablet computers compared to interactive voice response to improve subject recruitment in osteoporosis pragmatic clinical trials: feasibility, satisfaction, and sample size. Patient Prefer Adherence (2013) 0.76
Reply: To PMID 22473917. Arthritis Care Res (Hoboken) (2013) 0.76
Contributions of OMERACT to rheumatic disease research. Arthritis Rheum (2007) 0.76
Editorial: current concepts in arthroplasty. Open Orthop J (2011) 0.75
Health care costs in gout: what are these emerging data telling us? J Clin Rheumatol (2009) 0.75
A Real-World Study of Switching From Allopurinol to Febuxostat in a Health Plan Database. J Clin Rheumatol (2015) 0.75
Patient Burden of Axial Spondyloarthritis. J Clin Rheumatol (2017) 0.75
Patient Burden of Axial Spondyloarthritis. J Clin Rheumatol (2017) 0.75